相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DYRK1A inhibitors for disease therapy: Current status and perspectives
Tong Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
Pavithra Shyamsunder et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
PROTAC targeted protein degraders: the past is prologue
Miklos Bekes et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Analysis of CDK12 alterations in a pan-cancer database
Elizabeth Pan et al.
CANCER MEDICINE (2022)
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate
Jinge Zhao et al.
BJU INTERNATIONAL (2022)
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
Jing Gao et al.
HAEMATOLOGICA (2022)
3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders
Radek Jorda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
Xiaosa Chang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Hui Liu et al.
CANCER RESEARCH (2021)
CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer
Tamara L. Lotan et al.
CLINICAL CANCER RESEARCH (2021)
Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma
Baishan Jiang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
CDK12 inhibition enhances sensitivity of HER2+breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT
Hui Li et al.
EUROPEAN JOURNAL OF CANCER (2021)
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration
Bikang Yang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2021)
Discovery and resistance mechanism of a selective CDK12 degrader
Baishan Jiang et al.
NATURE CHEMICAL BIOLOGY (2021)
Novel Mechanisms of Molecular Glue-Induced Protein Degradation
Shanique Alabi
BIOCHEMISTRY (2021)
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Guoqiang Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types
Andrew Elliott et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2021)
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Sebastian M. Dieter et al.
CELL REPORTS (2021)
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma
Cun Wang et al.
GUT (2020)
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β-catenin Signaling
Fang Peng et al.
CURRENT CANCER DRUG TARGETS (2020)
CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
Xiao Wang et al.
EUROPEAN UROLOGY (2020)
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Melissa A. Reimers et al.
EUROPEAN UROLOGY (2020)
Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death
Xiaoou Xu et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Targeting autophagy-related protein kinases for potential therapeutic purpose
Honggang Xiang et al.
ACTA PHARMACEUTICA SINICA B (2020)
The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma
Po-Ming Chow et al.
CANCER LETTERS (2020)
Rapid block of pre-mRNA splicing by chemical inhibition of analog-sensitive CRK9 inTrypanosoma brucei
Ujwala Gosavi et al.
MOLECULAR MICROBIOLOGY (2020)
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Jonathan Chou et al.
CANCER DISCOVERY (2020)
Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin Signaling Pathways in Human Cancers
Dhanasekhar Reddy et al.
FRONTIERS IN ONCOLOGY (2020)
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
Bastien Nguyen et al.
EUROPEAN UROLOGY (2020)
CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
Zheng Fan et al.
SCIENCE ADVANCES (2020)
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome
Meijia Liu et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value
Pichaya Thanindratarn et al.
EUROPEAN SPINE JOURNAL (2020)
Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13
Yao Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Mikolaj Slabicki et al.
NATURE (2020)
Rational discovery of molecular glue degraders via scalable chemical profiling
Cristina Mayor-Ruiz et al.
NATURE CHEMICAL BIOLOGY (2020)
CDK12 globally stimulates RNA polymerase II transcription elongation and carboxyl-terminal domain phosphorylation
Michael Tellier et al.
NUCLEIC ACIDS RESEARCH (2020)
CDK12: a potential therapeutic target in cancer
Fatemeh Emadi et al.
DRUG DISCOVERY TODAY (2020)
PROTAC: A promising technology for cancer treatment
Xin Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lu Lv et al.
ELIFE (2020)
CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer
Yi Li et al.
CANCER LETTERS (2020)
CDK12 and PAK2 as novel therapeutic targets for human gastric cancer
Hui Liu et al.
THERANOSTICS (2020)
CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability
Seung H. Choi et al.
GENES & DEVELOPMENT (2019)
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation
Malgorzata Krajewska et al.
NATURE COMMUNICATIONS (2019)
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling
Hee-Joo Choi et al.
EMBO REPORTS (2019)
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Ian Bayles et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
Tianlu Huang et al.
CELL DEATH & DISEASE (2019)
Targeted drug combination therapy design based on driver genes
Lilian Zs�kai et al.
Oncotarget (2019)
The PROTAC technology in drug development
Yutian Zou et al.
CELL BIOCHEMISTRY AND FUNCTION (2019)
Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V
Xu Zhang et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium
Arno L. Greenleaf
TRANSCRIPTION-AUSTIN (2019)
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma
Amanda Balboni Iniguez et al.
CANCER CELL (2018)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
David A. Quigley et al.
CELL (2018)
Structure-Based Design of Selective Noncovalent CDK12 Inhibitors
Jeffrey W. Johannes et al.
CHEMMEDCHEM (2018)
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Dewan Md Sakib Hossain et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells
Loredana Zocchi et al.
Oncotarget (2018)
Discovery of 3-Benzyl-1-(trans-4-(5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors
Masahiro Ito et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling
Kate L. Henry et al.
SCIENCE SIGNALING (2018)
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng et al.
ELIFE (2018)
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors
Yang Gao et al.
CELL CHEMICAL BIOLOGY (2018)
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Jerry F. Tien et al.
NUCLEIC ACIDS RESEARCH (2017)
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors
Hana Paculová et al.
TUMOR BIOLOGY (2017)
The emerging roles of CDK12 in tumorigenesis
Hana Paculova et al.
CELL DIVISION (2017)
Combined venetoclax and alvocidib in acute myeloid leukemia
James Bogenberger et al.
ONCOTARGET (2017)
Cdk12 is essential for embryonic development and the maintenance of genomic stability
H-C Juan et al.
CELL DEATH AND DIFFERENTIATION (2016)
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
David A. Alagpulinsa et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications
Tatiana Popova et al.
CANCER RESEARCH (2016)
Role and therapeutic potential of CDK12 in human cancers
Rosaria Chila et al.
CANCER TREATMENT REVIEWS (2016)
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Tinghu Zhang et al.
NATURE CHEMICAL BIOLOGY (2016)
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
Shawn F. Johnson et al.
CELL REPORTS (2016)
Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas
Bartlomiej Bartkowiak et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2015)
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Concepcion Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing
Kaiwei Liang et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT(MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
Chaoxin Hu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex
Kingsley M. Ekumi et al.
NUCLEIC ACIDS RESEARCH (2015)
Heterochromatin remodeling by CDK12 contributes to learning in Drosophila
Lixia Pan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
Xiu-Xiu Chen et al.
ONCOTARGET (2015)
Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex
Bartlomiej Bartkowiak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
A phase I trial of flavopiridol in relapsed multiple myeloma
Craig C. Hofmeister et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
Poorval M. Joshi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
Rachael Natrajan et al.
JOURNAL OF PATHOLOGY (2014)
NF-κB, an Active Player in Human Cancers
Yifeng Xia et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties
Mathieu Bibian et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
Brijal M. Desai et al.
PLOS ONE (2013)
The cyclin K/Cdk12 complex An emerging new player in the maintenance of genome stability
Dalibor Blazek
CELL CYCLE (2012)
The regulation of glial-specific splicing of Neurexin IV requires HOW and Cdk12 activity
Floriano Rodrigues et al.
DEVELOPMENT (2012)
Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is Required for the Phosphorylation of the C-Terminal Domain of RNA Polymerase II
S. -W. Grace Cheng et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Functional genomics identifies therapeutic targets for MYC-driven cancer
Masafumi Toyoshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
Georg Feldmann et al.
CANCER BIOLOGY & THERAPY (2011)
Phosphorylation mechanism and structure of serine-arginine protein kinases
Gourisankar Ghosh et al.
FEBS JOURNAL (2011)
NF-κB inducing kinase: A key regulator in the immune system and in cancer
Yee Mon Thu et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
CRK7 modifies the MAPK pathway and influences the response to endocrine therapy
Elizabeth Iorns et al.
CARCINOGENESIS (2009)
Cyclin-dependent kinases: a family portrait
Marcos Malumbres et al.
NATURE CELL BIOLOGY (2009)
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
K. Bettayeb et al.
ONCOGENE (2008)
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai et al.
NATURE REVIEWS CANCER (2006)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
Monoclonal antibody successes in the clinic
JM Reichert et al.
NATURE BIOTECHNOLOGY (2005)
The crystal structure of human CDK7 and its protein recognition properties
G Lolli et al.
STRUCTURE (2004)
分享论文
